Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Baclofen
Drug ID BADD_D00209
Description Baclofen is a gamma-aminobutyric acid (GABA) agonist used as a skeletal muscle relaxant used for the relief of painful and uncomfortable muscle spasms caused by a variety of conditions. It is particularly useful in treating muscle spasticity associated with spinal cord injury. This drug has recently been studied for the management of alcohol withdrawal, however, a conclusion has not been made regarding baclofen efficacy in this condition. [A173908,A173911,A173938] This drug was first approved by the FDA in 1992.[F4570]
Indications and Usage Baclofen is indicated for the treatment of spasticity resulting from multiple sclerosis and is particularly useful for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity.[L39434] It may also be of value in the treatment of patients with spinal cord injuries or diseases. Baclofen is also indicated as an intrathecal injection for the management of severe spasticity of cerebral or spinal original in patients 4 years of age and older.[L39429] Patients who respond to bolus intrathecal doses of baclofen, and who require chronic therapy, can use an implantable intrathecal pump to administer baclofen via long-term infusion.
Marketing Status approved
ATC Code M03BX01
DrugBank ID DB00181
KEGG ID D00241
MeSH ID D001418
PubChem ID 2284
TTD Drug ID D01AJY
NDC Product Code 72888-145; 0395-8032; 12658-0508; 12658-0583; 51552-0613; 63275-9992; 65015-635; 82245-0205; 0172-4096; 55154-7635; 55700-974; 61919-093; 61919-095; 63629-2081; 68071-2841; 70257-412; 70257-561; 70518-3467; 71335-0344; 71335-1664; 71335-1796; 71335-9681; 71610-446; 71610-452; 72162-1079; 72162-1080; 73320-003; 80425-0157; 68055-001; 68055-002; 76420-930; 82393-207; 29300-344; 50090-4682; 50090-5855; 55700-403; 63629-2130; 67457-563; 67544-671; 69528-301; 70121-2496; 70121-2503; 70257-560; 70518-2804; 70934-918; 71205-474; 71225-140; 0603-2406; 0615-8467; 49452-0807; 50218-010; 51014-7035; 51927-2007; 68055-003; 68055-945; 68055-947; 81371-6004; 29300-343; 50268-107; 52536-600; 55289-757; 63629-2129; 63629-2131; 64896-077; 68071-2289; 0527-1330; 70518-3089; 0603-2407; 62135-473; 63187-274; 67457-564; 68071-3468; 70257-563; 70518-3115; 71610-614; 0615-3541; 71930-006; 71930-007; 72888-146; 73320-001; 80425-0081; 80425-0205; 48954-469; 10135-533; 16714-072; 25021-679; 0172-4097; 50090-2493; 50090-5838; 63187-280; 63629-1227; 63629-2083; 63629-2084; 67457-562; 68071-2414; 70121-2502; 70511-124; 70771-1448; 70771-1449; 71335-0103; 71335-0949; 71930-066; 0615-8411; 73320-002; 12658-0480; 12658-0582; 0904-7341; 53747-075; 68055-946; 76420-931; 29300-474; 0115-1011; 50268-105; 50268-106; 52817-319; 52817-320; 61919-026; 64896-078; 68788-8333; 70121-2504; 70511-122; 70511-123; 70518-0362; 70756-288; 71610-660; 72789-312; 72888-010; 72888-147; 76420-242; 80425-0080; 0904-6476; 46014-1035; 46014-1124; 51927-0146; 65628-100; 68981-007; 79572-003; 43063-865; 45865-452; 55154-7876; 63739-480; 64896-076; 68071-3001; 68134-401; 70710-1286; 71335-1356; 72888-011; 12658-0562; 17511-130; 38779-0388; 51927-0147; 65628-101; 16714-071; 25021-678; 52817-321; 55700-408; 59651-394; 60687-503; 63187-147; 63187-313; 68071-5249; 68071-5252; 68788-9246; 70121-2501; 71335-1797; 71335-9638; 0615-3542; 76420-241; 80425-0156; 0832-1054; 0832-1055; 80425-0282; 38779-3209; 62991-1013; 68055-004; 25021-680; 50090-6149; 62135-472; 63629-1224; 63629-1225; 63629-1228; 63629-2080; 63629-2082; 63739-479; 68084-868; 68788-6384; 0527-1337; 70257-414; 70257-562; 70511-121; 70518-0215; 70710-1285; 70710-1609; 70756-085; 70771-1586; 71335-1643; 0615-8412; 80425-0112; 12658-0448; 12658-0462; 76420-165; 25021-681; 60687-514; 62135-474; 63629-1226; 63629-2128; 68071-3407; 68084-855; 0527-1333; 70121-2505; 70257-416; 70518-2662; 70518-3614; 70756-289; 71335-0206; 0615-8466; 72888-009; 83008-015; 0904-6475; 12658-0584; 10135-532; 59651-395; 68055-948; 0115-1010; 0115-1012; 43063-864; 45865-355; 52652-6001
UNII H789N3FKE8
Synonyms Baclofen | Baclophen | PCP-GABA | beta-(Aminomethyl)-4-chlorobenzenepropanoic Acid | Chlorophenyl GABA | GABA, Chlorophenyl | beta-(p-Chlorophenyl)-gamma-aminobutyric Acid | Clofen | Gen-Baclofen | Gen Baclofen | GenBaclofen | Genpharm | Apo-Baclofen | Apo Baclofen | ApoBaclofen | Atrofen | Baclofène-Irex | Baclofène Irex | BaclofèneIrex | Baclofen AWD | AWD, Baclofen | Lebic | Lioresal | Liorésal | Nu-Baclo | Nu Baclo | NuBaclo | PMS-Baclofen | PMS Baclofen | PMSBaclofen | Baclospas | Ba-34,647 | Ba34,647 | Ba-34647 | Ba34647 | CIBA-34,647-BA | CIBA34,647BA
Chemical Information
Molecular Formula C10H12ClNO2
CAS Registry Number 1134-47-0
SMILES C1=CC(=CC=C1C(CC(=O)O)CN)Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Posterior reversible encephalopathy syndrome17.13.02.0070.000348%
Slow speech19.19.02.004; 17.02.08.0160.000104%Not Available
Neuropsychiatric syndrome19.07.03.009; 17.02.10.0140.000104%Not Available
Muscle tone disorder17.05.02.014; 15.05.04.0170.000390%Not Available
Catheter site extravasation12.07.02.012; 08.02.02.0120.000223%Not Available
Complication associated with device08.07.01.0110.002925%Not Available
Multiple organ dysfunction syndrome08.01.03.0570.000696%
Anal incontinence17.05.01.021; 07.01.06.0290.000313%
Frustration tolerance decreased19.04.02.0160.000153%Not Available
Apnoeic attack22.02.01.027; 17.02.05.0510.000070%Not Available
Cervical spinal stenosis17.10.02.006; 15.10.04.0060.000070%Not Available
Confabulation19.10.03.0090.000070%Not Available
Drop attacks17.05.02.016; 15.05.04.0180.000070%Not Available
Head banging19.11.03.0070.000070%Not Available
Impulsive behaviour19.18.01.0010.000104%Not Available
Locked-in syndrome17.01.04.0190.000174%Not Available
Palmoplantar keratoderma23.01.01.0070.000070%Not Available
Persecutory delusion19.10.01.0070.000139%Not Available
Posturing19.11.03.008; 17.01.02.0240.000139%Not Available
Pupil fixed17.02.11.008; 06.05.03.0120.000348%Not Available
Sciatic nerve neuropathy17.09.02.0140.000174%Not Available
Intracranial hypotension17.02.05.036; 12.01.10.0080.000522%Not Available
Self esteem inflated19.05.02.0030.000070%Not Available
Progressive multiple sclerosis17.16.01.0060.000070%Not Available
Neurodegenerative disorder17.02.10.0240.000070%Not Available
Hypertensive emergency24.08.01.0040.000070%Not Available
Communication disorder19.19.01.0080.000153%Not Available
Foaming at mouth17.02.05.056; 08.01.03.070; 07.05.05.0190.000139%Not Available
Multimorbidity08.01.03.0750.000070%Not Available
Stress cardiomyopathy24.04.04.026; 02.04.01.0120.000522%Not Available
The 16th Page    First    Pre   16 17 18 19    Next   Last    Total 19 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene